A Missouri federal court has ruled that a plaintiff that did not respond to a cease and desist letter and instead filed a declaratory action in federal court cannot take advantage of the first-filed rule.
In a sign of the increasing litigation over lucrative patent rights for digital cameras, four of the world’s top camera makers are trying to fend off a lawsuit by a tiny Michigan company that already has won large jury awards against major photography companies such as Canon Inc. and Sony Corp.
International law firm Kelley Drye & Warren has staffed up in Chicago and is launching a new patent group to bolster its intellectual property practice.
Canadian telecom company Nortel Networks Corp. has settled a copyright and trade secrets case it brought in July against Arbinet-thExchange Inc., an internet-based business-to-business trading exchange.
Dutch drug maker Akzo Nobel has agreed to pay $36 million to settle a class-action lawsuit brought by U.S. states and public sector health purchasers over an alleged attempt to evergreen patents on the former blockbuster antidepressant Remeron.
A federal district court judge has denied drug maker Pfizer Inc.'s motion for a preliminary injunction to block Alpharma's sale of a generic version of epilepsy drug Neurontin.
In a risky move, Alpharma Inc. on Friday launched a generic version of Pfizer’s blockbuster epilepsy drug Neurontin without waiting for a court ruling on Pfizer's motion for a preliminary injunction.
A hearing on Pfizer’s motion for a preliminary injunction against a generic version of epilepsy drug Neurontin was adjourned Thursday with no decision.
Dutch conglomerate Akzo Nobel and its subsidiary Organon USA have agreed to settle litigation over its patents for antidepressant Remeron for $59.8 million, but the company still faces risks of class-action complaints.
Biopharma company Immunomedics, Inc. has settled its patent infringement lawsuit against Cytogen Corp. and C.R. Bard, Inc. for an undisclosed payment and without any admission of fault or liability, the companies said.
A federal judge has set the trial date for Canadian chip maker Mosaid Technologies’ closely watched patent lawsuit against South Korean rival Samsung for February 1, 2005.
A court hearing on a motion by drug maker Pfizer Inc. to bar Alpharma Inc. from rolling out a generic version of the Pfizer epilepsy drug Neurontin has been postponed until Oct. 1, Alpharma said on Monday.
The judge presiding over Pfizer’s lawsuit against generics maker Alpharma Inc. over patent rights to the epilepsy drug Neurontin has adjourned a preliminary-injunction hearing until Monday morning.
Swiss pharmaceutical company Novartis AG has sued Israeli generics maker Teva Pharmaceutical Industries Ltd. to block a generic version of its hypertension drug Lotrel.
German drug maker Schwarz Pharma will continue to seek damages from Israel's Teva in a patent dispute over Schwarz's hypertension drug Univasc, even though Teva agreed to pull its supply of its generic version of the drug pending the outcome of litigation between the two companies.
Israeli generics maker Teva Pharmaceutical Industries Ltd. has agreed to stop selling its generic version of Schwarz Pharma AG's Univasc hypertension drug until the resolution of a patent infringement lawsuit in New Jersey district court.
A federal judge has ordered Samsung to pay Mosaid Technologies $566,000 in sanctions, chiding the Korean electronics maker for destroying and failing to produce evidence during discovery in a suit over patents for dynamic random access memory technology.
A federal court has denied drug maker Pfizer Inc.’s attempt to bar Ivax Corp. from introducing a generic version of blockbuster epilepsy drug Neurontin.
Ivax Corp.’s decision Wednesday to launch a generic version of Pfizer Inc.'s blockbuster epilepsy drug Neurontin in the midst of a drawn-out patent dispute is seen by analysts as a bold but risky move.
A condom maker has sued a rival over a patent for a special “twist” designed to pleasure both men and women.